

18 June 2025

Bioxyne enters German market with €3,200,000 (A\$5.6m) minimum Manufacture and Supply Agreement

[Bioxyne Stürmt den deutschen Markt mit Herstellungs- und Liefervertrag im Wert von mindestens ~\$5,6 Millionen]

Bioxyne Limited (ASX: BXN) (Bioxyne or Company), through its subsidiary Breathe Life Sciences (BLS), is pleased to announce it has entered the German cannabis market, executing a commercial agreement to supply a minimum of 1,600 kg of GMP medical cannabis flower API and finished product. The cannabis flower will be manufactured by Bioxyne's subsidiary Breathe Life Sciences under EU GMP certified standards for export to Germany.

Key Highlights:

- BLS has executed a manufacture and supply agreement with Farmakem d.o.o. as Buyer and Adrex Pharmaceuticals GmbH, a leading importer, manufacturer, and distributor of Cannabis in Germany.
- The supply agreement commits Farmakem and Adrex to purchase and distribute a minimum of 1.6 tons (1,600kg) of Cannabis Flower Product manufactured by BLS in FY2026.
- BLS and Adrex have registered 14 of its Australian manufactured cannabis strains with BfArM (the largest drug approval authority in Europe) in Germany, which authorizes the import and distribution of the product in the German market.
- BLS and Adrex are working together to establish BLS brands, including Dr Watson®, in the German market.
- Under the agreement, BLS expects to generate a minimum of A\$5.6m (€3.2m) in revenue in FY2026
- The first delivery of 580kg is scheduled for September 2025, with a second shipment planned for November.

Positive Outlook for FY2026

Bioxyne is positioned for significant growth in FY2026, attributable to further expansion of its business in Australia as well as entry into new high-growth opportunity markets including the UK, Germany and other EU countries.

The German medical cannabis market is growing rapidly following deregulation in early 2025 and is expected to overtake Australia's \$1b-per-year medcan market in 2026.

For personal use only

Cannabis Flower represents over 95% of Germany's medical cannabis sales, and all product going into Germany must be manufactured under GMP-certification. As a GMP certified manufacturer BLS has scale and cost advantages with which the company expects to win significant business in Germany and other European markets.

About Farmaken d.o.o.

Farmakem is a licensed EU GMDP certified manufacturer and supplier of medical cannabis products to European markets.

About Adrex Pharmaceuticals GmbH:

Adrex is a licensed importer, manufacturer, and wholesale distributor of cannabis in Germany.

This announcement has been approved by the Board for release to the ASX.

About Bioxyne Limited:

Bioxyne Limited is a licensed Australian pharmaceutical company manufacturing and distributing novel medicines and active pharmaceutical ingredients including medicinal cannabis, MDMA, and Psilocybin.

<https://bioxyne.com>

For further information, please contact:

Bioxyne Limited
Investor Relations

info@bioxyne.com
Phone: +61 2 9078 8180



About Bioxyne

Bioxyne Limited (ASX:BXN) is an Australian-headquartered international consumer health and pharmaceutical company (incorporated in 2000) with a focus on clinically effective health and wellness products, psychotropic and investigational medicines.

About Breathe Life Sciences (BLS)

Breathe Life Sciences (“BLS”) is a wholly owned subsidiary of Bioxyne Ltd (BXN:ASX) and GMP-licensed manufacturer, wholesaler, importer and exporter of controlled substances (S3, S4, S8, S9), including medicinal cannabis, Psilocybin, and MDMA.

BLS was founded in 2018 and has quickly expanded into a multi-national business focused on alternative therapeutics and investigational medicines. The company’s corporate head office is in Sydney, with operations and licensed manufacturing, warehousing, import/export, sales and distribution centres in Queensland (Australia), Nagoya (Japan), Manchester (UK), and Prague (Czechia).

The BLS business model is focused on manufacturing final dose form medicines, sales and distribution. BLS sources raw materials and API from suppliers in 5 continents and is the Australian market leading manufacturer of therapeutic goods including cannabis, MDMA, and Psilocybin.

Outside of Australia the BLS Group operates in pharmaceuticals, medical cannabis, consumer health products, and novel foods (CBD). In the UK, Europe and Japan, the Company engages in the following activities:

- a) Owner of Dr Watson® brand in the UK, Japan, Australia and New Zealand. Internationally recognized for its cannabis-based food supplements, lifestyle products, functional mushrooms and nootropics, and prescription medicines in Australia.
- b) Contract manufacture and wholesale of raw materials and cannabinoid extracts in Japan, UK and Europe.
- c) Contract / white label manufacture of consumer health products for brands in Japan, UK and Europe in company-owned facilities.
- d) Research and development of novel medicines.
- e) Direct sales via online and wholesale of BLS-owned consumer brands, such as Dr Watson®
 - **United Kingdom:** drwatsoncbd.com
 - **Japan:** nolcbrn.com
 - **UK / EU:** breathelifesciences.com
- f) Export and supply of medicinal cannabis products and manufacturing services to UK and European markets.

Corporate: bioxyne.com

Australia: bls.com.au

International: breathelifesciences.com

